Healthcare -
Biotechnology - NASDAQ - US
$ 11.83
2.78 %
$ 1.24 B
Market Cap
-8.16
P/E
INCOME STATEMENT
EFFICIENCY
Earnings Waterfall
Edgewise Therapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 159 M |
| Operating Income | -159 M |
| Other Expenses | -25 M |
| Net Income | -134 M |
Income Statement
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| GROSS PROFIT | ||||||
| Cost Of Revenue | 0 | 1.7 | 0.5 | 0.3 | 0.2 | 0.1 |
| Gross Profit | 0 | (1.7) | (0.5) | (0.3) | (0.2) | (0.1) |
| OPERATING INCOME | ||||||
| Operating Expenses | 158.8 | 114.4 | 22.1 | 43.2 | 17.2 | 9.9 |
| Selling, General and Administrative Expenses | 31.9 | 23.5 | 5.5 | 11.0 | 2.2 | 1.3 |
| Research and Development Expenses | 127.0 | 89.4 | 16.6 | 32.2 | 15.0 | 8.6 |
| Operating Income | (158.8) | (114.4) | (22.1) | (43.2) | (17.2) | (9.9) |
| PRE-TAX INCOME | ||||||
| Interest Income Expense | 0 | 0 | 4.0 | 0 | 0 | 0 |
| Total Other Income | 25.0 | 14.2 | 4.0 | 0.4 | 69 K | 0.2 |
| Pre-Tax Income | (133.8) | (100.2) | (19.4) | (42.8) | (17.1) | (9.7) |
| NET INCOME | ||||||
| Tax Provision | 0 | 0 | (4.0) | (0.7) | 69 K | (0.2) |
| Net Income | (133.8) | (100.2) | (15.4) | (42.1) | (17.1) | (9.5) |
| EPS | 1.45 | 1.57 | 0.29 | 0.85 | 0.35 | 0.19 |